S6 Fig -

Daemen, Anneleen; Udyavar, Akshata R.; Sandmann, Thomas; Li, Congfen; Bosch, Linda J. W.; O’Gorman, William; Li, Yijin; Au-Yeung, Amelia; Takahashi, Chikara; Kabbarah, Omar; Bourgon, Richard; Hegde, Priti; Bais, Carlos; Thakur, Meghna Das

doi:10.1371/journal.pone.0262198.s006

pone.0262198.s006.pdf (662.82 kB)

S6 Fig -

journal contribution

posted on 2021-12-31, 18:45 authored by Anneleen Daemen, Akshata R. Udyavar, Thomas Sandmann, Congfen Li, Linda J. W. Bosch, William O’Gorman, Yijin Li, Amelia Au-Yeung, Chikara Takahashi, Omar Kabbarah, Richard Bourgon, Priti Hegde, Carlos Bais, Meghna Das Thakur

Kaplan-Meier curves for the AVANT signature in the AVANT BEP dataset split by treatment arm as indicated, for DFS: (a) FOLFOX-4, (b) FOLFOX-4 + bevacizumab, and (c) XELOX + bevacizumab; and for OS: (d) FOLFOX-4, (e) FOLFOX-4 + bevacizumab, and (f) XELOX + bevacizumab. P-values correspond to a log-rank test.

(PDF)